Comparison · NCT03238235-b26ab96f
Givinostat vs Placebo: Count of Participant Who Lose Ambulation During the Study (From Baseline to Month 12)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Givinostat vs Placebo: Count of Participant Who Lose Ambulation During the Study (From Baseline to Month 12). Trial comparisons, record NCT03238235-b26ab96f. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03238235-b26ab96f
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.102 | wilson | |
| Risk in group 2 | 0 | 0 | 0.184 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.184 | 0.102 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Givinostat | Givinostat oral suspension (10 mg/mL) twice daily in a fed state~Givinostat: suspension of Givinostat (10 mg/mL) | 0 | 34 | OG000 |
| Group 2 | Placebo | Placebo oral suspension (10 mg/mL) twice daily in a fed state~Placebo: suspension manufactured to mimic Givinostat | 0 | 17 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Count of Participant Who Lose Ambulation During the Study (From Baseline to Month 12)
- Description
- Percentage of patients losing the ability to ambulate from baseline to the end of study (Visit 11 or Month 12)
- Time frame
- from baseline to the end of month 12
- Population
Intent-To-Treat Analysis (ITT) Set: all patients assigned treatment by randomization who received at least one dose of study medication. According to the intent to treat principle, patients were analyzed according to the treatment assigned. Efficacy analyses were performed on the ITT set.
Source ClinicalTrials.gov
Trial
- Title
- Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Becker Muscular Dystrophy
- NCT number
- NCT03238235
- Phases
- PHASE2
- Conditions
- Becker Muscular Dystrophy
- Interventions
- Givinostat, Placebo
- Lead sponsor
- Italfarmaco
- Results first posted
- 2024-11-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03238235?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03238235-b26ab96f